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Background: Following neoadjuvant chemotherapy for operable gastroesophageal cancer, lymph node metastasis is the only
validated prognostic variable; however, within lymph node groups there is still heterogeneity with risk of relapse. We
hypothesized that gene profiles from neoadjuvant chemotherapy treated resection specimens from gastroesophageal cancer
patients can be used to define prognostic risk groups to identify patients at risk for relapse.
Patients and methods: The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial (n¼ 202 with
high quality RNA) samples treated with perioperative chemotherapy were profiled for a custom gastric cancer gene panel using
the NanoString platform. Genes associated with overall survival (OS) were identified using penalized and standard Cox
regression, followed by generation of risk scores and development of a NanoString biomarker assay to stratify patients into risk
groups associated with OS. An independent dataset served as a validation cohort.
Results: Regression and clustering analysis of MAGIC patients defined a seven-Gene Signature and two risk groups with
different OS [hazard ratio (HR) 5.1; P< 0.0001]. The median OS of high- and low-risk groups were 10.2 [95% confidence interval
(CI) of 6.5 and 13.2months] and 80.9months (CI: 43.0months and not assessable), respectively. Risk groups were independently
prognostic of lymph node metastasis by multivariate analysis (HR 3.6 in node positive group, P¼ 0.02; HR 3.6 in high-risk group,
P¼ 0.0002), and not prognostic in surgery only patients (n¼ 118; log rank P¼ 0.2). A validation cohort independently confirmed
these findings.
Conclusions: These results suggest that gene-based risk groups can independently predict prognosis in gastroesophageal
cancer patients treated with neoadjuvant chemotherapy. This signature and associated assay may help risk stratify these
patients for post-surgery chemotherapy in future perioperative chemotherapy-based clinical trials.
Key words: gastric cancer, oesophageal cancer, perioperative chemotherapy, prognostic biomarker, MAGIC Trial, statistical
regression analysis
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Introduction
Perioperative chemotherapy is one standard treatment option for
patients with resectable gastric and esophageal cancer; this multi-
modality therapy leads to cure for 50% of patients [1–4].
Improved post-operative risk stratification would be valuable in
order to focus development of novel treatments on patients who
are most likely to relapse. However, extraction of DNA and RNA
from pre-chemotherapy biopsy samples is challenging and limits
the applicability of molecular stratification for making pre-
operative treatment decisions. Therefore, a unique approach to
prognostic stratification using post-chemotherapy resection
specimens may have clinical utility.
The MAGIC trial was a large phase III randomized trial in
which patients were treated with either six cycles of perioperative
epirubicin, cisplatin and 5-fluorouracil (ECF) chemotherapy
(three cycles pre-and post-operatively) plus surgery, or with sur-
gery alone. The results of the trial supported a survival benefit for
perioperative chemotherapy treated patients and established
platinum-fluoropyrimidine-based perioperative chemotherapy
as one standard of care for resectable gastroesophageal cancer [1].
We hypothesized that by performing transcriptomic analysis on
resection specimens from patients treated with perioperative
chemotherapy in the MAGIC trial distinct subgroups of patients
with different survival outcomes can be identified. Herein, we
present the results of this analysis carried out in patients from the
MAGIC trial, and validated in a second, independent, similar co-
hort of patients.
Methods
Patient samples
Formalin-fixed paraffin-embedded (FFPE) resection specimens
(n¼ 202 with high quality RNA) with clinicopathologic information
were available for gene profile analysis from those patients randomized
within the MAGIC trial (n¼ 503; Figure 1A) [5]. The validation cohort
consists of a prospectively collected database of resected gastroesopha-
geal cancer patient samples at the Royal Marsden Hospital (RMH) and
Guys and St Thomas Hospital (GSTT) in London, UK [6]. From this
database a translational protocol (PROGRESS) was funded by the
RMH and Institute of Cancer Research/National Institute of Cancer
Research Biomedical Research Centre. Approval was obtained from
institutional review boards (MAGIC: IRAS 11/LO/0566; PROGRESS:
IRAS 15/EE/0228).
Gene expression profiling
The samples from MAGIC trial were profiled for two hundred genes
(including 110 characterizing intrinsic gastric cancer subtypes; others
were genes frequently amplified/deleted in gastroesophageal cancer or
related to chemotherapy sensitivity) [7, 8] and PROGRESS (subset of
genes from above) study were profiled using NanoString platform
MAGIC trial
population
(n = 503)
A
B Gene expression profiles of 200 gene panel (7 quality
control failed) for 202 MAGIC trial patients with
tumor samples available
Surgery Only
(n = 118)
Perioperative ECF
(n = 84)
Fit penalized Cox repeatedly 100
times splitting the data into 
training and test sets
14 genes selected with
frequency of more than 80%
Fit standard Cox to the selected
14 genes to find the signature
7 gene signature selected at 5%
significance level.
Generate risk scores and find
risk groups
Use the signature to generate
risk scores in the Surgery Only
patients and find risk groups
No significant risk groups
Two or three risk groups of
different prognosis value
were identified
Independent validation of the signature and risk
groups using 47 identically treated patients from
PROGRESS study using supervised analysis
Perioperative ECF
(n = 250)
Surgery Only
(n = 253)
NanoString data
(n = 84)
NanoString data
(n = 118)
Figure 1. Consort diagram and ﬂow chart of statistical methods. (A) CONSORT diagram highlighting which of the MAGIC trial patients had
samples taken and included in this study. (B) Flow chart showing the statistical pipeline followed to select genes, ﬁnd risk groups and valid-
ate them. NanoString represents nCounter assay from NanoString Technologies.
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(see supplementary methods, available at Annals of Oncology online for
more details on RNA isolation, NanoString methods, and quality control
measures) [9].
Gene selection and risk group identification
The pipeline employed to stratify patients into different risk groups is
highlighted in Figure 1B. Firstly, genes expressed in at least 75% of the
samples were selected. Genes associated with OS in the perioperative
group were identified using penalized Cox regression[10] by repeatedly
splitting (100 times) the data into training/testing random sets and select-
ing genes with frequency of more than 80% occurrence as potential
markers for prognosis. Next, a standard Cox regression model was fitted
to the expression data of the selected genes to identify robust genes sig-
nificantly (P< 0.05) associated with OS. Finally, the risk score (risk of
mortality), Ri, for the ith patient in the perioperative group were deter-
mined as follows:
Ri ¼
Xp
j¼1
logðexp½bjÞ  Xj
where p is the number of selected genes, bj is the regression coefficient
(natural-logarithm of hazard ratio; HR) for Xj expression for gene j. The
risk scores were then used to stratify patients into different risk groups
based on the median cut-off or unsupervised K-means clustering ap-
proach. The prognostic value of the risk groups was evaluated using
multivariate Cox analysis.
Results
In the MAGIC trial, 503 patients were randomized to surgery
alone or perioperative chemotherapy of which 456 (91%) under-
went surgery and had a date of surgery available for survival
analysis. There was no significant differences in OS between
patients who had tissue available included in this study
for nCounter analysis and those who did not (log-rank P¼ 0.3;
supplementary Figure S1A, available at Annals of Oncology on-
line). The quality custom nCounter gene expression profile from
resected FFPE samples for 202 MAGIC patients was used (see
Figure 1A, CONSORT diagram), and their clinicopathologic
details are detailed in Table 1.
Using penalized Cox regression analysis in 84 chemotherapy
plus surgery treated patients, we identified 14 predictive genes
with at least 80% frequency (Figures 1B and 2A; supplementary
Figure S1B–D and Table S1, available at Annals of Oncology on-
line). Standard Cox regression analysis on the selected 14 genes
resulted in 7 genes (CDH1, ELOVL5, EGFR, PIP5K1B, FGF1,
CD44v8.10 and TBCEL; named as GC-RiskAssigner signature),
only prognostic in the perioperative chemotherapy group
(supplementary Table S2A, available at Annals of Oncology on-
line). In order to stratify patients into different risk groups, we
computed the risk score for each patient, i.e. a numerical measure
quantifying the risk of mortality. The risk scores were generated
by multiplying the expression values of the seven genes (GC-
RiskAssigner) with their corresponding HR (representing the risk
associated with each gene). Finally, patients were divided into ei-
ther two (low/high) or three (low, moderate and high) risk
groups based on their risk scores.
When patients were dichotomized based on whether they fall
into lower half (low-risk) or upper half (high-risk) of their
median risk scores (median cut-off) (Figure 2B), the median OS
for the high-risk group was 10.2 months (95% CI 6.5–
13.2 months) compared with 80.9 months (95% CI 43.0 months–
not assessable) for the low-risk group [HR¼ 5.1 (95% CI 2.8–9.2);
P< 0.0001; Figure 2C]. Alternatively, when the risk scores
were clustered into three risk groups using a clustering method K-
means, the median OS for the high-risk group was 6.5 months
(95% CI 5.1–11.6) and 22.6 months (17.1–54.3) for the moderate-risk
group whilst it was not assessable for the low-risk group
(Figure 2D and E, Cox P< 0.0001). Rates of 1, 3 and 5 years OS
for patients in both two and three risk groups are shown in sup-
plementary Table S2B, available at Annals of Oncology online.
Multivariate analysis including nodal status was carried out to
determine whether the risk groups were an independent predict-
or of OS in the perioperative chemotherapy treated patients.
Table 2 shows that risk groups remained predictive of OS when
controlling for lymph node status, only known confounder of
survival [5]. In contrast, when the GC-RiskAssigner was applied
to the surgery only patients, none of the seven genes were associ-
ated with OS (supplementary Table S2A, available at Annals of
Oncology online) and there was no significant difference in the
OS between the two risk groups derived using median cut-off
(log-rank P¼ 0.2; Figure 3A).
We evaluated the performance of the seven genes from the
GC-RiskAssigner signature in predicting the risk groups using
receiver operating characteristic (ROC) curve analysis using
MAGIC samples. An average area under the curve was high with
0.97 (95% CI 0.97 and 0.98) as assessed that suggests the robust-
ness of the GC-RiskAssigner signature in predicting the two
perioperative risk groups (supplementary Figure S2A, available
at Annals of Oncology online). Next, we generated prediction
analysis of microarray (PAM) [11] based centroids (which rep-
resent the summarized gene expression of each gene in each risk
group) for the two median-based risk groups from MAGIC
samples (supplementary Table S3A and Figure S2B, available at
Table 1. Clinicopathologic characteristics of MAGIC patient cohort
Variable Value Perioperative
chemotherapy
n5 84 (%)
Surgery only
n5 118 (%)
Sex Male 68 (81) 87 (74)
Female 16 (19) 31 (26)
Site of tumor Stomach 69 (82) 95 (80)
Lower oesophagus 5 (6) 9 (8)
O-G junction 10 (12) 14 (12)
Age Median 64 62
IQR 56–70 54–70
Range 34–77 27–80
Histology Diffuse 11 (13) 26 (22)
Intestinal 73 (87) 85 (72)
Mixed 0 (0) 7 (6)
Nodal-status Yes 50 (60) 71 (60)
No 17 (20) 21 (18)
NA 17 (20) 26 (22)
O-G, oesophagogastric; IQR, interquartile range; NA, not applicable.
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Annals of Oncology online) using the GC-RiskAssigner signature
and developed an nCounter platform biomarker assay for the
same genes. The patients from the PROGRESS validation co-
hort (n¼ 47; Table 3) were assigned to the risk groups based on
the maximum correlation coefficient values after correlating
(Pearson’s correlation) each patient expression profile with the
GC-RiskAssigner signature PAM centroids. The risk of death
(HR¼ 2.7; 95% CI 1.3–5.6; P¼ 0.004; Figure 3B; supplemen-
tary Table S3B, available at Annals of Oncology online) in the
high-risk group was almost three times the risk of the low-risk
group in PROGRESS cohort. The median OS was 20.4 months
(95% CI 12.4–32.5) in the high-risk group compared with
39.4 months (95% CI 30.5–not reached) in the low-risk group.
Rates of 1, 3 and 5 years OS for patients in the two predicted risk
groups are shown in supplementary Table S3C, available at
Annals of Oncology online. Multivariate analysis of risk score
and lymph node metastasis confirmed the independent prog-
nostic value of risk groups (Cox P¼ 0.01) also in the validation
cohort (Figure 3C).
Discussion
Platinum- and fluoropyrimidine-based perioperative chemo-
therapy is a common treatment of patients with operable gastroe-
sophageal adenocarcinoma that is endorsed by international
guidelines [4]. In this study, patients from MAGIC trial were
risk stratified into distinct groups with different survival out-
comes following preoperative chemotherapy using a seven-gene
(GC-RiskAssigner) signature. These findings were validated in
an independent cohort of patients treated with identical chemo-
therapy plus surgery using our NanoString assay for the GC-
RiskAssigner signature. Importantly, risk group based on the
GC-RiskAssigner signature provided prognostic information in-
dependent of lymph node metastasis, which is the best established
prognostic variable so far identified for patients treated with peri-
operative chemotherapy [5]. These results are potentially import-
ant because, in future, clinical trials could be designed using gene
signature-based risk groups to select the patients most likely to
develop recurrent cancer in which to develop novel or more in-
tensive postoperative therapies.
Figure 2. Gene selection using penalized Cox regression and determination of risk groups in MAGIC perioperative chemotherapy treated
patients. (A) A plot showing frequency (between 0 and 1) at which genes were selected by penalized Cox regression and the corresponding
regression coefﬁcients. Horizontal grey dashed line identiﬁes 14 genes selected at frequency of 0.8. High expression of genes with positive
regression coefﬁcients, denoted by red dots, is associated with worst prognosis whilst those in purple are associated with good prognosis.
(B) A boxplot of risk groups identiﬁed by dichotomizing the GC-RiskAssigner risk scores based on median cut-off. (C) The Kaplan–Meier plots
highlighting the prognostic value of the two risk groups derived using median of risk scores as a cut-off. (D and E) A boxplot and Kaplan–
Meir plot of three risk groups identiﬁed by K-Means clustering.
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Prognostic gene signatures that predict survival after surgical
resection have been validated in other cancers, and have been
adopted into routine clinical practice in hormone receptor posi-
tive breast cancer and to a lesser extent in colon cancer [12, 13].
These and other prognostic signatures were developed for use in
patients who have undergone primary surgery without
neoadjuvant chemotherapy and inform the likely benefit from
adjuvant chemotherapy based on a recurrence risk calculated on
gene expression in an untreated primary tumor [12–14]. A post-
chemotherapy gene expression signature was developed in
metastatic gastric cancer and validated in a second cohort as
prognostic for survival [15], however, to our knowledge this is
Figure 3. Determination of the risk groups in the surgery only patients and validation of the risk groups in a validation cohort. Kaplan–Meier
plots showing the difference in OS between (A) the risk groups from surgery only patients and (B) the predicted risk groups in the validation
cohort (C) Multivariate analysis of risk groups and nodal status for the validation cohort. HR and P denote hazard ratios and P-values,
respectively.
Table 2. Multivariate analysis of overall survival in chemotherapy treated MAGIC patients
Clinical variables Median-based risk groups K-means-based risk groups
HR (95% CI) P HR (95% CI) P
Nodal status—Yes 3.6 (1.2–10.7) 0.02 3.5 (1.2–10.3) 0.03
Risk groups
High risk 3.6 (1.8–7.2) 0.0002 13.8 (4.5–42.8) <0.0001
Moderate risk NA NA 5.5 (2.6–11.8) <0.0001
NA, not applicable.
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the first signature which has been developed for patients with
resected gastric cancer. Although a gene signature predictive of
response to neoadjuvant chemotherapy is the ideal, the frequent-
ly scanty tissue available in diagnostic specimens renders this
challenging. Therefore, development of a prognostic signature
based on post-chemotherapy gene expression profiles that can be
measured in the more abundant tissue of the surgical resection
may be a pragmatic solution. Dynamic changes in gene expres-
sion following chemotherapy have been associated with survival
in ovarian cancer pre-clinical models and in breast cancer
patients treated in the Investigation of Serial Studies to Predict
Your Therapeutic Response with Imaging and Molecular
Analysis (I-SPY) trial [16, 17]; however, to our knowledge this
study is the first to present a prognostic model in patients treated
with neoadjuvant chemotherapy for resectable gastroesophageal
cancer, and to do so in the context of a randomized clinical trial.
The limitations of the current manuscript include its retro-
spective nature, the pre-specified approach to gene selection and
the modest size of the validation cohort. Although the gene panel
from which the seven-Gene Signature was derived contains only
200 genes, these genes were selected for their biologically import-
ant roles in gastroesophageal cancer [7]. Importantly, several of
the genes included in the signature have been identified a priori
as having a prognostic role in gastric cancer. These include EGFR,
amplification of which is associated with adverse survival out-
comes in several series, and CD44v8-10, a marker of gastric cancer
stem cells, which are associated with chemoresistance and worse
survival in chemotherapy treated gastric cancer patients [18–21].
Furthermore, although the validation PROGRESS cohort is not a
clinical trial dataset, patients in this cohort had been treated with
an almost identical chemotherapy to patients in MAGIC. We
note that the validation cohort contained more patients with
esophageal or junctional cancer, compared with MAGIC, which
contains a majority (75%) of gastric cancers. However, this could
also be perceived as a strength in terms of the generalizability of
the results. As the contribution of each individual chemotherapy
component in MAGIC is not known, an appropriate next step
would be to validate the prognostic signature in patients who
have not received epirubicin, cisplatin and 5-fluorouracil chemo-
therapy. This is of particular importance because of the recent
presentation of the results of the FLOT4-AIO study of periopera-
tive docetaxel, oxaliplatin and 5-fluorouracil (FLOT) which
demonstrated improved OS compared with ECF/X chemother-
apy [3].
In conclusion, we demonstrate that our signature identified in
post-chemotherapy resection specimens from patients with gas-
troesophageal cancer treated in the MAGIC trial can help to de-
termine prognosis in patients who have been treated with
perioperative chemotherapy. Importantly, this signature can be
used in conjunction with nodal status to classify patients into risk
groups after preoperative chemotherapy. We suggest further ex-
ploration of this signature in contemporary trial datasets such as
FLOT4-AIO and future design of risk stratified clinical trials to
improve survival for patients with resectable gastroesophageal
cancer.
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